Point State Capital LP Biomarin Pharmaceutical Inc Transaction History

Point State Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $4.41 Million - $5.35 Million	-59,042 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $18.1 Million - $22.5 Million	-249,109 Reduced 80.84%	59,042 $5.18 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $4.17 Million - $7.6 Million	57,981 Added 23.18%	308,151 $23.4 Million
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $4.52 Million - $7.05 Million	56,793 Added 29.37%	250,170 $30.9 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $18.5 Million - $25.1 Million	-258,863 Reduced 57.24%	193,377 $16.3 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $29.1 Million - $39.1 Million	452,240 New	452,240 $38.2 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.